Feed aggregator

'Visual system' protein appears to be key for stabilizing the body's circadian rhythms

Rss Feed - Thu, 12/28/2023 - 21:56
Scientists at the Johns Hopkins University School of Medicine and the National Institutes of Health have identified a protein in the visual system of mice that appears to be key for stabilizing the body's circadian rhythms by buffering the brain's response to light.

$15 million NCI grant awarded to investigate a type of radiation therapy for hard-to-treat cancers

Rss Feed - Thu, 12/28/2023 - 21:44
The Radiopharmaceutical Therapy and Dosimetry Lab at Johns Hopkins Medicine, headed by George Sgouros, Ph.D., has been awarded a $15 million grant, to be dispersed over the next five years, from the National Cancer Institute at the National Institutes of Health.

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

Rss Feed - Thu, 12/28/2023 - 21:28
A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

Angelica gigas extract emerges as a potential treatment for vascular disease

Rss Feed - Thu, 12/28/2023 - 21:07
A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 15, Issue 23, entitled, "Angelica gigas extract inhibits acetylation of eNOS via IRE1α sulfonation/RIDD-SIRT1-mediated posttranslational modification in vascular dysfunction."

New insights on better diagnosis and treatment of ischemic cholecystitis

Rss Feed - Thu, 12/28/2023 - 20:59
Ischemic cholecystitis is a form of gallbladder inflammation that occurs without gallstones or another form of external compression.

Lisocabtagene maraleucel: A cost-effective second-line treatment for relapsed/refractory DLBCL

Rss Feed - Thu, 12/28/2023 - 20:07
Lisocabtagene maraleucel (liso-cel), a CAR T-cell therapy, is a cost effective second line treatment for relapsed and refractory (hard to treat) diffuse large B-cell lymphoma (r/r DLBCL), according to a study published today in Blood Advances.

Integrated care may not be the silver bullet for mental health treatment, study finds

Rss Feed - Thu, 12/28/2023 - 20:01
Health care systems in the United States have gradually embraced the concept that mental health should be treated on par with physical health, especially in light of increased rates of anxiety and depression during and after the COVID-19 pandemic.

Next-gen sequencing identifies thousands of cancer patients missing out on immunotherapy

Rss Feed - Thu, 12/28/2023 - 19:45
Brigham researchers' findings from next-generation sequencing suggest that revising current cancer care guidelines could allow approximately 6,000 more patients in the U.S. to benefit from immunotherapy treatment each year

New non-steroidal anti-inflammatory can inhibit the cytokine storm and preserve innate immunity

Rss Feed - Thu, 12/28/2023 - 19:34
Very early in the COVID-19 pandemic clinical trials in patients hospitalized with COVID-19 confirmed that corticosteroids like dexamethasone reduced mortality, but they were harmful when applied at the first COVID-19 symptoms, due to the weakening of innate antiviral immunity, leading to delayed viral clearance and adverse outcomes in severe viral pneumonias.

Sepsis greatly reduces the chances of returning to work, study finds

Rss Feed - Thu, 12/28/2023 - 13:39
A few years ago, the World Health Organization estimated that blood poisoning, or sepsis, is involved in one in five deaths in the world. 11 million people die from sepsis each year, of which nearly 3 million are children.

Pages